EGFR and neoplasm: However, recently published data from a multi-institutional analysis of 86 patients retreated with anti-EGFR therapy suggest that clinical factors such as the number of anti-EGFR-free lines of therapy, the length of the anti-EGFR-free time interval, the primary tumor side, and the time from diagnosis to retreatment are not associated with rechallenge response rate or PFS (72).